Advertisement

Topics

Top-line results are in from Clementia’s Phase 2 trial of Palovarotene

15:24 EDT 18 Oct 2016 | Biotechnology Focus

MONTREAL, QC-Clementia Pharmaceuticals has released top-line results from its Phase 2 clinical trial investigating palovarotene, a retinoic acid receptor gamma agonist (RAR?), for the treatment of fibrodysplasia ossificans progressiva (FOP). FOP is an extremely rare but serious disease in which an accumulation of heterotopic ossification (HO, extraskeletal bone) in muscle and soft tissue progressively restricts [&hellip

The post Top-line results are in from Clementia’s Phase 2 trial of Palovarotene appeared first on Biotechnology Focus.

Original Article: Top-line results are in from Clementia’s Phase 2 trial of Palovarotene

NEXT ARTICLE

More From BioPortfolio on "Top-line results are in from Clementia’s Phase 2 trial of Palovarotene"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...